- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Alt
Recent news which mentions Alt
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 03, 2022
From Benzinga
7 Biotech Stocks to Buy for Q3
July 18, 2022
From InvestorPlace
89 Biggest Movers From Friday
June 21, 2022
From Benzinga
69 Biggest Movers From Yesterday
June 10, 2022
From Benzinga
110 Biggest Movers From Friday
May 16, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Earnings Scheduled For March 14, 2022
March 14, 2022
From Benzinga
From Benzinga
Are Intranasal Sprays The Next $36 Billion Trend in Vaccine Stocks?
February 08, 2022
From Motley Fool
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
January 31, 2022
Tickers
ALT
From Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
December 30, 2021
From Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
From Benzinga
52 Biggest Movers From Yesterday
September 30, 2021
From Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 29, 2021
From Benzinga
33 Stocks Moving In Wednesday's Mid-Day Session
September 29, 2021
From Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 29, 2021
From Benzinga
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
September 28, 2021
Tickers
ALT
From Benzinga
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
September 28, 2021
Tickers
ALT
From InvestorPlace
Why Altimmune Stock Is Under Pressure Today
September 28, 2021
From Motley Fool
See Why Altimmune Stock Plunged After Obesity Trial Data
September 28, 2021
Tickers
ALT
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.